Artiva Biotherapeutics (ARTV) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.63
- Estimate
- -$0.64
- Surprise
- +1.9%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Artiva Biotherapeutics (ARTV) reported a narrower loss than forecast — diluted EPS of -$0.63 against the -$0.64 estimate (a 1.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARTV Sell at 4.8/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +1.9% surprise compares with a -6.4% four-quarter average.
What argues against it
- Concentration risk — Pipeline: AlloNK
- DATA_ISSUE: analyst_target_implausible (raw $35.80 vs price $11.08 — ratio 3.2×). Rejected, falling back to technical TP.
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $11.09
- Price target
- $12.02
- Stop
- $10.30
- Upside to target
- +8.4%
Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.
ARTV at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $552.9M
- P/E (fwd)
- -4.3
- 52-week range
- $2.22–$14.53
- Off 52-week high
- 23.7%
- RSI (14)
- 45
- Volume vs avg
- 0.21×
- Score today
- 4.8/10